Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer

Journal of International Oncology››2016,Vol. 43››Issue (3): 167-170.doi:10.3760/cma.j.issn.1673-422X.2016.03.002

Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer

Li Dongliang*, Li Haiyan, Han Lei, Duan Yijun, Sun Junning, Zhang Ning, Su Wen

Department of Thoracic Surgery, Tumor Hospital of Shanxi, Taiyuan 030013, China

Online:2016-03-08Published:2016-02-03
Contact:Su Wen, Email: 13509731663@163.com E-mail:Email: 13509731663@163.com
Supported by:

Shanxi Provincial Health Department of Science and Technology Research Project (2011048)

Abstract

Abstract:Objective To investigation the expressions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors in non-small cell lung cancer (NSCLC) and their clinical significances. Methods The serum expression levels of TRAIL in 79 cases of NSCLC and 80 cases of normal subjects were detected by enzyme-linked immunosorbent assay (ELISA). The expressions of TRAIL-R2 and TRAIL-R4 in 42 cases of NSCLC and matched normal tissues were detected by immunohistochemistry. The relationships among TRAIL, TRAIL-R2, TRAIL-R4 and clinicopathologic features of NSCLC were analyzed. Results The expression of TRAIL in NSCLC patients was lower than that in normal human ［(994.3±293.0)ng/ml vs. (1 141.7±266.1)ng/ml,t=3.29,P=0.00］. The expression of TRAIL was closely correlated with clinical stage (F=2.28,P=0.00) and differentiated degree（t=5.76,P=0.00). The positive expression rate of TRAIL-R2 in NSCLC was 73.8% (31/42), significantly lower than that in the normal tissue 100.0% (42/42) (χ²=3.88,P=0.05). The expression of TRAIL-R2 was closely correlated with clinical stage (χ²=27.89,P=0.00) and differentiated degree (χ²=9.50,P=0.00). The positive expression rate of TRAIL-R4 in NSCLC was 81.0% (34/42), significantly higher than that in the normal tissue 50.0% (21/42) (χ²⁼7.34,P=0.01). The expression of TRAIL-R4 was also closely correlated with clinical stage (χ²=17.82,P=0.00) and differentiated degree (χ²=4.47,P=0.03). There was a negative correlation between the expression of TRAIL-R2 and TRAIL-R4 in NSCLC(r=-0.67,P=0.01). Conclusion The decrease of TRAIL and TRAIL-R2 and increase of TRAIL-R4 expression may promote the occurrence and development of NSCLC, and they may provide targets for clinical treatment of NSCLC.

Key words:Carcinoma, non-small-cell lung,TNF-related apoptosis-inducing ligand,Receptors, TNF-related apoptosis-inducing ligand

Li Dongliang, Li Haiyan, Han Lei, Duan Yijun, Sun Junning, Zhang Ning, Su Wen. Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(3): 167-170.

References

［1］ Wiley SR, Schooley K, Smolak PJ, et al. Identification and chara-cterization of a new member of the TNF family that induces apoptosis［J］. Immunity, 1995, 3(6): 673-682. ［2］ Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies［J］. J Immunol, 2005, 175(9): 5586-5590. ［3］ Marini P, Schmid A, Jendrossek V, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis［J］. BMC Cancer, 2005, 5: 5. DOI: 10.1186/1471-2407-5-5. ［4］ Arts HJ, De Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma［J］. Gynecol Oncol, 2004, 92(3): 794-800. DOI: 10.1016/j.ygyno.2003.11.054. ［5］ Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosisinducing ligand［J］. Hum Pathol, 2006, 37(10): 1286-1294. DOI: 10.1016/j.humpath.2006.04.026. ［6］ Leithner K, Stacher E, Wurm R, et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy［J］. Lung Cancer, 2009, 65(1): 98-104. DOI: 10.1016/j.lungcan.2008.10.015. ［7］ Spierings DC, De Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage Ⅲ non-small cell lung cancer tumors［J］. Clin Cancer Res, 2003, 9(9): 3397-3405. ［8］ Sanlioglu AD, Dirice E, Aydin C, et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells［J］. BMC Cancer, 2005, 5: 54. DOI: 10.1186/1471-2407-5-54. ［9］ Kim YJ, Lee SA, Myung SC, et al. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ova-rian carcinoma cells by promoting activation of apoptosisrelated proteins［J］. Mol Cell Biochem, 2012, 359(1/2): 3343. DOI: 10.1007/s11010-011-0997-9. ［10］ Singh TR, Shankar S, Chen X, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo［J］. Cancer Res, 2003, 63(17): 5390-5400. ［11］ Duiker EW, Meijer A, Van Der Bilt AR, et al. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carci-noma cells to rhTRAIL-induced apoptosis［J］. Br J Cancer, 2011, 104(8): 1278-1287. DOI: 10.1038/bjc.2011.84. ［12］ Bonomi P, Greco FA. Results of a phase 2 trial of HGS-ETR1(agonistic human monoclonal antibody to TRAIL receptor1)in subjects with relapsed/recurrent nonsmall cell lung cancer(NSCLC)［J］. Med Oncol, 2006, 23(2): 120-191.

[1]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong.Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases[J]. Journal of International Oncology, 2017, 44(4): 271-273.
[2]	XU Jian, LI Jing-Dong.Tumor necrosis factor-related apoptosis inducing ligand and its receptorsin hepatocellular carcinoma[J]. Journal of International Oncology, 2013, 40(8): 605-607.